DS-8201a + Physician's Choice
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasm, Gastrointestinal
Conditions
Neoplasm, Gastrointestinal
Trial Timeline
Nov 2, 2017 → Dec 11, 2020
NCT ID
NCT03329690About DS-8201a + Physician's Choice
DS-8201a + Physician's Choice is a phase 2 stage product being developed by Daiichi Sankyo for Neoplasm, Gastrointestinal. The current trial status is completed. This product is registered under clinical trial identifier NCT03329690. Target conditions include Neoplasm, Gastrointestinal.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03329690 | Phase 2 | Completed |
Competing Products
20 competing products in Neoplasm, Gastrointestinal
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AB0024 | Gilead Sciences | Phase 1 | 32 |
| TTI-237 | Pfizer | Phase 1 | 32 |
| 852A | Pfizer | Phase 1 | 32 |
| EO-3021 + Ramucirumab (CYRAMZA®) + Dostarlimab | CSPC Pharmaceutical Group Limited | Phase 1 | 32 |
| LY2780301 | Eli Lilly | Phase 1 | 33 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| IMC-3C5 | Eli Lilly | Phase 1 | 33 |
| LY3295668 | Eli Lilly | Phase 1/2 | 41 |
| Abemaciclib + Clarithromycin | Eli Lilly | Phase 1 | 33 |
| Abemaciclib + Fulvestrant | Eli Lilly | Phase 2 | 52 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Fulvestrant + Placebo | Eli Lilly | Phase 3 | 77 |
| Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + Leucovorin | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Tadalafil + Gemcitabine | Eli Lilly | Phase 1 | 33 |
| enzastaurin | Eli Lilly | Phase 2 | 52 |
| enzastaurin + gemcitabine | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Darolutamide + LHRH agonist/antagonist | Eli Lilly | Phase 1 | 33 |